“If it’s Covid, Paxlovid.”
That’s how Pfizer markets its Covid-19 antiviral, at the same time as the entire results of a find out about published within the New England Journal of Medicine this week provides further evidence that the tablet is probably not as effective in vaccinated adults and the ones at low possibility for severe symptoms.
The overall find out about results had been published in NEJM on Wednesday, even though Pfizer released the initial results again in 2022. Paxlovid was once granted complete approval remaining Would possibly to regard mild-to-moderate Covid-19 in adults at prime possibility for developing severe Covid-19, after it was once first made availready under an emergency use authorization in 2021.
Free up this newsletter straight away by way of changing into a unfastened subscriber.
You’ll get get right of entry to to unfastened articles every month, plus you’ll be able to customise what newsletters get delivered on your inbox every week, together with breaking information.
